SHARES ELIGIBLE FOR FUTURE SALE
General
Future sales of substantial amounts of our Common Shares in the public market, or the perception that such sales may occur, could adversely affect the prevailing market price of our Common Shares or impair our ability to raise equity capital in the future. No prediction can be made as to the effect, if any, future sales of our Common Shares, or the availability of our Common Shares for future sales, will have on the market price of our Common Shares prevailing from time to time. The sale of substantial amounts of our Common Shares in the public market, or the perception that such sales of our Common Shares could occur, could adversely affect the prevailing market price of our Common Shares.
Sales of Restricted Securities
A total of 116,898,062 of our Common Shares were outstanding as of May 17, 2024. The Selling Shareholders are offering 9,000,000 Common Shares (or 10,350,000 Common Shares if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full). After giving effect to the offering, 42,455,389 (or 43,805,389 Common Shares if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full) will be freely tradable without restriction under the Securities Act, unless purchased by our “affiliates,” as that term is defined in Rule 144 under the Securities Act. The remaining Common Shares that will be outstanding after this offering are “restricted securities” within the meaning of Rule 144 under the Securities Act. Restricted securities may be sold in the public market only if registered under the Securities Act or if they qualify for an exemption from registration, including an exemption under Rule 144, Rule 701 or Regulation S, which are summarized below.
Of the 116,898,062 Common Shares outstanding immediately following this offering, 54.24% of our Common Shares (or 53.08% of our Common Shares if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full) are subject to lock-up agreements as described herein. See “—Lock-up Agreement” and “—IPO Assistance and Lock-Up Agreement.”
As defined in Rule 144, an “affiliate” of an issuer is a person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with the issuer.
Lock-up Agreement
Prior to the settlement of this offering, we and the Selling Shareholders, have agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares or such other securities for a period of 90 days after the date of this prospectus. These agreements are described below under the section captioned “Underwriting.”
IPO Assistance and Lock-Up Agreement
In connection with our initial public offering, Daniel Burrows, Allan Decleir, Denise Brown-Branch and Ian Houston (collectively, the “Insurance Group Executives” and each, an “Insurance Group Executive”), Richard Brindle, Richard Coulson, Hinal Patel and Charles Mathias (collectively, the “TFP Executives” and each, a “TFP Executive”) and FIHL entered into an initial public offering assistance and lock-up agreement (the “IPO Assistance and Lock-Up Agreement”). Under the terms of the IPO Assistance and Lock-Up Agreement, (i) the TFP Executives and Daniel Burrows agreed, subject to limited exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
75